🇺🇸 SPECTINOMYCIN in United States

27 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Back Pain — 3 reports (11.11%)
  2. Chest Discomfort — 3 reports (11.11%)
  3. Dry Mouth — 3 reports (11.11%)
  4. Dyspnoea — 3 reports (11.11%)
  5. Panic Attack — 3 reports (11.11%)
  6. Pharyngeal Oedema — 3 reports (11.11%)
  7. Treatment Failure — 3 reports (11.11%)
  8. Drug Ineffective — 2 reports (7.41%)
  9. Obliterative Bronchiolitis — 2 reports (7.41%)
  10. Pathogen Resistance — 2 reports (7.41%)

Source database →

SPECTINOMYCIN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SPECTINOMYCIN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for SPECTINOMYCIN in United States?

Marketing authorisation holder not available in our data.